Helix BioPharma Corp. (TSX: HBP, OTC PINK: HBPCD, FRANKFURT: HBP0) announced its financial results for the three- and six-month periods ended January 31, 2026, revealing a reduced net loss but a precarious cash position that underscores the challenges facing small-cap biotech firms in the current capital markets environment. The company reported a net and total comprehensive loss of $694,000 for the three months ended January 31, 2026, compared to $1,375,000 in the same period last year, and a loss of $1,702,000 for the six-month period, down from $2,711,000. The improvement was attributed to the conclusion of the LDOS006 clinical trial in metastatic pancreatic adenocarcinoma and reduced research activities, partially offset by higher operating, general, and administrative expenses.
However, the company's cash reserves have dwindled to $31,000 as of January 31, 2026, from $1,996,000 a year earlier. Helix expects that existing cash is insufficient to meet working capital and capital expenditure needs for the next twelve months or to complete current research and development activities. A significant financing setback occurred when Quantum Global Ventures AG, which had agreed to purchase 18,538,889 common shares at $1.80 per share for gross proceeds of $33,370,000, declared bankruptcy after the reporting period, resulting in no proceeds being received. The company is now pursuing alternative financing, having signed a term sheet with Alumni Capital Limited, though specific terms remain confidential due to confidentiality obligations.
CEO Thomas Mehrling, MD, PhD, stated, 'While our current financial position reflects a challenging capital markets environment for small-cap biotech companies, our focus remains firmly on securing the financing necessary to advance Helix into its next phase.' He noted that management and the board are actively pursuing opportunities to secure approximately twelve months of operating runway, which would allow the company to pursue near-term objectives, including listing on a U.S. securities exchange. 'While there is still work to be done, we have reason to be cautiously optimistic as we intensify these efforts and expect to communicate further on our roadmap to achieve this goal soon,' Mehrling added.
The company's pipeline includes L-DOS47, a clinical-stage antibody-enzyme conjugate targeting CEACAM6-expressing tumors, which has completed Phase Ib studies in non-small cell lung cancer. Helix is also developing next-generation bi-specific antibody-drug conjugates based on the same targeting foundation, as well as pre-IND candidates LEUMUNA™ for post-transplant leukemia relapse and GEMCEDA™, an oral gemcitabine prodrug. The financial results and management's discussion are available on SEDAR+ at www.sedarplus.ca and on the company's website at https://www.helixbiopharma.com/filings-and-financials/.
The news highlights the critical juncture for Helix as it strives to secure funding to advance its oncology pipeline and achieve a U.S. listing, which could provide greater access to capital markets. The failure of the Quantum Global Ventures financing underscores the volatility and risk inherent in small-cap biotech investments, making the outcome of ongoing financing discussions pivotal for the company's survival and future development.
